News

Filter by year

March 10, 2026

Zemcelpro® (dorocubicel) positive results in high- and very high-risk blood cancers to be reported at the EBMT 2026 Annual Meeting

– Zemcelpro® (dorocubicel) achieved remarkable and clinically meaningful survival results in patients with high- and very high-risk acute leukemias and myelodysplastic syndromes – Topline results from two Phase 2 studies to be presented on March 23, 2026 at the EBMT Annual Meeting in Madrid, Spain MONTREAL, March 10, 2026 – ExCellThera Inc. (ExCellThera), a world leader […]

Read more

February 16, 2026

Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany

The NUB designation for Zemcelpro® (dorocubicel) enables hospitals to immediately apply for temporary, supplementary reimbursement for its use. MONTREAL, February 16, 2026 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, and its wholly owned subsidiary Cordex Biologics (Cordex), announced that Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy, has […]

Read more